Abbott Laboratories (ABT) announced that the Ministry of Health, Labor and Welfare or MHLW in Japan has approved the XIENCE Xpedition Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease or CAD, the most common form of heart disease.
The company said that XIENCE Xpedition is supported by the clinical evidence of the XIENCE family of drug eluting stents and features a new delivery system designed to navigate smoothly through clogged blood vessels in the heart during an angioplasty procedure, particularly in patients with complicated heart vessel anatomy.
The company noted that XIENCE Xpedition employs a specialized balloon that helps physicians open difficult-to-treat blockages and ensures the stent fits securely against the walls of the blood vessel once implanted. The catheter that carries the stent has a low-profile design that allows it to move smoothly through the body and heart to the site of the blockage.
XIENCE Xpedition is available in the United States, Europe, the Middle East and parts of Asia. XIENCE PRIME and XIENCE V are available in countries throughout the world, the company said.
For comments and feedback: editorial@rttnews.com